Dr. Yalong Wang is an Instructor in the Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center. He earned his B.S. in Animal Science from Shanghai Jiao Tong University, Ph.D. in Cell Biology from the University of Chinese Academy of Sciences, and completed postdoctoral training in immunology and epigenetics. His research spans molecular biology, immunology, and cancer epigenetics, with notable contributions including the discovery that NLRC5 regulates MHC class I antigen presentation (Cell Research, 2012), the role of DHX15 in Paneth cell antimicrobial protein expression (PNAS, 2021), and the development of widely used pan-methylarginine antibodies (Methods, 2022). Dr. Wang created Snd1-KO/KI mice to elucidate methylarginine reader functions (Biochemical Journal, 2023) and identified the SART3 HAT domain as a novel SDMA reader (Cell Reports, 2024). He has received multiple honors, including the 2022 EMC Travel Award, and has industry experience in antibody development and screening.
Dr. Yalong Wang is an Instructor in the Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center. He earned his B.S. in Animal Science from Shanghai Jiao Tong University, Ph.D. in Cell Biology from the University of Chinese Academy of Sciences, and completed postdoctoral training in immunology and epigenetics. His research spans molecular biology, immunology, and cancer epigenetics, with notable contributions including the discovery that NLRC5 regulates MHC class I antigen presentation (Cell Research, 2012), the role of DHX15 in Paneth cell antimicrobial protein expression (PNAS, 2021), and the development of widely used pan-methylarginine antibodies (Methods, 2022). Dr. Wang created Snd1-KO/KI mice to elucidate methylarginine reader functions (Biochemical Journal, 2023) and identified the SART3 HAT domain as a novel SDMA reader (Cell Reports, 2024). He has received multiple honors, including the 2022 EMC Travel Award, and has industry experience in antibody development and screening.